185 related articles for article (PubMed ID: 37509369)
1. Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy.
Vilbert M; Koch EC; Rose AAN; Laister RC; Gray D; Sotov V; Penny S; Spreafico A; Pinto DM; Butler MO; Saibil SD
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509369
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
[TBL] [Abstract][Full Text] [Related]
3. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
5. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Orloff M
Ocul Oncol Pathol; 2021 Jun; 7(3):168-176. PubMed ID: 34307327
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients.
Grynberg S; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Haisraely O; Lawrence Y; Ben-Betzalel G
Ther Adv Med Oncol; 2022; 14():17588359221131521. PubMed ID: 36339927
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
9. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
10. So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
Rodrigues M; Koning L; Coupland SE; Jochemsen AG; Marais R; Stern MH; Valente A; Barnhill R; Cassoux N; Evans A; Galloway I; Jager MJ; Kapiteijn E; Romanowska-Dixon B; Ryll B; Roman-Roman S; Piperno-Neumann S;
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336679
[TBL] [Abstract][Full Text] [Related]
11. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen CL; Kött J; Hartung TI; Torster LK; Gebhardt C
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945010
[TBL] [Abstract][Full Text] [Related]
12. Two Pyroptosis-Related Subtypes with Distinct Immune Microenvironment Characteristics and a Novel Signature for Predicting Immunotherapy Response and Prognosis in Uveal Melanoma.
Lei S; Li H
Curr Eye Res; 2022 Jun; 47(6):930-943. PubMed ID: 35348009
[TBL] [Abstract][Full Text] [Related]
13. New Treatment Horizons in Uveal and Cutaneous Melanoma.
Brănişteanu DE; Porumb-Andrese E; Porumb V; Stărică A; Moraru AD; Nicolescu AC; Zemba M; Brănişteanu CI; Brănişteanu G; Brănişteanu DC
Life (Basel); 2023 Jul; 13(8):. PubMed ID: 37629523
[TBL] [Abstract][Full Text] [Related]
14. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.
Han A; Schug ZT; Aplin AE
Trends Cancer; 2021 Aug; 7(8):671-681. PubMed ID: 34127435
[TBL] [Abstract][Full Text] [Related]
17. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
18. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract][Full Text] [Related]
19. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ; Sinnberg T; Gschwind A; Niessner H; Demidov G; Amaral T; Ossowski S; Bonzheim I; Röcken M; Riess O; Garbe C; Schroeder C; Forschner A
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825510
[TBL] [Abstract][Full Text] [Related]
20. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
